Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2025, ended June 30, 2025. Key Fiscal Fourth Quarter...
Related Questions
What was the revenue growth percentage in the fourth quarter and how does it compare to prior quarters?
How did the service revenue growth contribute to overall earnings and margins?
What were the primary drivers behind the strong service growth reported?
What were the terms and maturity profile of the debt refinancing, and how does it affect cash flow and leverage ratios?
What is the outlook for capital expenditures and R&D spending in FY26, and how might that affect profitability?
How does the FY26 guidance compare to analysts' consensus estimates and market expectations?
What are the key assumptions underlying the FY26 guidance, especially regarding service revenue and product sales?
How does Accuray’s Q4 performance and FY26 outlook compare to its main competitors in the radiation therapy market?
Are there any upcoming product launches, regulatory approvals, or pipeline developments that could impact future results?
How might the recent earnings and guidance influence the stock price and trading volume in the near term?